Antithrombotic Management of Acute Mesenteric Ischaemia

Completed

• Conditions: Acute Mesenteric Ischemia; Short Bowel Syndrome
• Interventions: Other: Survey

• Registration Number: NCT05706012
• Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Brief Summary

Guidelines on the acute and long-term pharmacological treatment of acute mesenteric ischaemia (AMI) recommend the use of thrombolytic, antiplatelet or anticoagulant therapy depending on the aetiology of AMI and the use of stenting but only few details are given on the choice of the drug, dose and duration of treatment. Besides, recommendations are mainly based on data on coronary, cerebral and other peripheral artery diseases and do also not take into account the altered drug absorption in patients with short bowel syndrome, in which AMI can result.This case-based survey will inform us on the current international clinical practice of long-term antithrombotic management of AMI.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-01-20
• Study First Submitted QC: 2023-01-20
• Study First Posted: 2023-01-31
• Study Start: 2023-06-30
• Status Verified: 2023-11
• Primary Completion: 2024-02-29
• Study Completion: 2024-02-29
• Last Update Submitted: 2024-05-07
• Last Update Posted: 2024-05-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

• gastro-enterologist or cardiologist with expertise in treating SBS patients resulting from AMI

Exclusion Criteria

• none

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Gastro-enterologists and anticoagulation specialists	Survey	An online survey will be sent to question current clinical practice in long-term antithrombotic management of AMI in SBS patients.

Primary Outcome Measures

Name	Time	Method
Type of antithrombotic therapy	April 2023	Overview of the type of long-term antithrombotic therapy that is prescribed in SBS patients with AMI, depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed

Secondary Outcome Measures

Name	Time	Method
Duration of antithrombotic therapy	April 2023	Overview of the duration of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.
Dose adjustments of antithrombotic therapy	April 2023	Overview of any dose adjustments of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.
Initial dose of antithrombotic therapy	April 2023	Overview of the initial dose of long-term antithrombotic therapy in SBS patients with AMI depending on the anatomy of the gastrointestinal tract, the aetiology of AMI and whether or not revascularisation of the occluding blood vessel has been performed.

Trial Locations

Locations (1)

University Hospitals Leuven; 🇧🇪 Leuven, Belgium